Bietti's crystalline dystrophy
Bietti's Crystalline Dystrophy (BCD) is a rare, inherited eye disorder characterized by the formation of crystal deposits in the cornea and retina. These deposits can lead to progressive vision loss and eventually blindness. The condition was first described by Italian ophthalmologist G. B. Bietti in 1937.
Etiology
BCD is caused by mutations in the CYP4V2 gene, which is involved in the metabolism of fatty acids. The exact mechanism by which these mutations lead to the formation of crystal deposits is not fully understood. However, it is believed that the mutations disrupt the normal function of the CYP4V2 protein, leading to an accumulation of lipids in the eye.
Symptoms
The primary symptom of BCD is the presence of yellow-white crystal deposits in the cornea and retina. These deposits can be seen during an eye examination. Other symptoms include progressive vision loss, night blindness, and a decrease in peripheral vision. In some cases, patients may also experience photophobia, or sensitivity to light.
Diagnosis
Diagnosis of BCD is based on the presence of characteristic crystal deposits in the eye, as well as genetic testing to identify mutations in the CYP4V2 gene. Other tests, such as electroretinography and optical coherence tomography, may also be used to assess the extent of retinal damage.
Treatment
There is currently no cure for BCD. Treatment is focused on managing symptoms and slowing the progression of the disease. This may include the use of low-vision aids, such as magnifying glasses and large-print materials, as well as counseling and support for coping with vision loss.
Prognosis
The prognosis for individuals with BCD varies. Some individuals may maintain functional vision into their 50s or 60s, while others may become legally blind by their 30s or 40s. The rate of progression can vary widely, even among individuals with the same mutation.
See also
References
<references />
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

